Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

计划入组 21 人 · 首次发布于 2025 年 2 月 26 日

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

计划入组 16 人 · 首次发布于 2020 年 2 月 18 日

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

计划入组 6 人 · 首次发布于 2014 年 9 月 30 日

MYD88 mutant lymphoma therapy

cMET-Exon 14/wt amp inhibitor (Pfizer)

KRAS G12C/D/V mutations PROGRAM（AnHorn Medicines）

Cogent Biosciences

United States

IDEAYA Biosciences

United States

Alector

United States

SPIMA Therapeutics Launches with Exclusive License for Myddosome Inhibitor SPM001

Breakthrough Developments in Waldenström Macroglobulinemia Treatment: BTK Inhibitors and Novel Therapies Show Promise

SPIMA Therapeutics Launches with Focus on Peptide-Based Immunotherapies for Unmet Needs